The Gummy Project to serve Vancouvers Shakespeare Festival
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The Gummy Project (GUMY) announced that the company has received a repeat order from its existing customer, Flair Airlines
  • Flair Airlines is Canada’s only independent ultra low-cost carrier with 14 Boeing jets currently in operation with a goal of reaching 50 aircraft by 2026
  • The Gummy Project sells low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species
  • The Gummy Project Inc. (GUMY) is up 50.00 per cent, trading at C$0.015 per share as of 10:55 am ET

The Gummy Project (GUMY) announced that the company has received a repeat order from its existing customer, Flair Airlines.

Flair Airlines is Canada’s only independent ultra low-cost carrier with 14 Boeing jets currently in operation. Its goal is to reach 50 aircraft by 2026. Flair currently serves 28 destinations in Canada, USA and internationally.

Charlie Lamb, President & CEO of The Gummy Project, commented on the news.

“We are very pleased to receive our second repeat order from an existing customer. This is another vote of confidence that our customers are very much enjoying our gummies and strongly embracing our mandate to support endangered keystone species. We look forward to building upon the momentum that the Company has created as we continue to accelerate revenue generation and brand awareness.”

The Gummy Project is a growing community of individuals and organizations who believe small contributions can add up to something big. It sells low-sugar, plant-based gummy products while raising money (and awareness) to support endangered keystone species.

The company prides itself as the only “better for you” candy company that is built to support the planet’s most precious species and ecosystems. It educates the future generation on the steps to take today, to ensure a viable tomorrow.

The Gummy Project Inc. (GUMY) is up 50.00 per cent, trading at C$0.015 per share as of 10:55 am ET.


More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" EnWave (TSXV:ENW) signs technology evaluation agreement with Canadian cannabis cultivator

EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.